Esmolol contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Esmolol}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER ..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Contraindications== | |||
BREVIBLOC (Esmolol Hydrochloride) is contraindicated in patients with: | |||
:*'''Severe [[sinus bradycardia]]''': May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)]. | |||
:*'''Heart block''' greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and :*'''cardiac arrest''' [see Warnings and Precautions (5.2)]. | |||
:*'''Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)]. | |||
:*'''Decompensated [[heart failure]]''': May worsen [[heart failure]]. | |||
:*'''[[Cardiogenic shock]]''': May precipitate further cardiovascular collapse and cause [[cardiac arrest]]. | |||
:*'''IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. | |||
:*'''[[Pulmonary hypertension]]''': May precipitate cardiorespiratory compromise. | |||
:*'''[[Hypersensitivity reactions]]''', including anaphylaxis, to esmolol or any of the inactive ingredients of the product ([[cross-sensitivity]] between beta blockers is possible).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 18:36, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
BREVIBLOC (Esmolol Hydrochloride) is contraindicated in patients with:
- Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
- Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and :*cardiac arrest [see Warnings and Precautions (5.2)].
- Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
- Decompensated heart failure: May worsen heart failure.
- Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.
- IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil.
- Pulmonary hypertension: May precipitate cardiorespiratory compromise.
- Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).[1]
References
Adapted from the FDA Package Insert.